Abstract: Objective To observe the adverse effect and strategy of low dose pegylated-interferon (Peg-IFN) plus ribavirin (RBV) on patients with recurrent hepatitis C after liver transplantation. Methods The data of patients with recurrent hepatitis C after liver transplantation and treated with low dose Peg-IFN plus RBV were collected. The abnormality of routine blood test, function of liver and kidney, depression and alopecia were recorded. The clinical manifestation of depression and alopecia were recorded and treated properly. Results There were 22 cases who received low dose pegylated-interferon plus ribavirin treatment after liver transplantation. Among whom 22.7% (5/22) presented abnormal liver function, 68.2% (15/22) with granulocytopenia, 50% (11/22) with decreases of hemoglobin, 27.2% (6/22) with thrombocytopenia, 22.7% (5/22) with symptoms of irritability. One patient dropped out the study because of thrombocytopenia, the other 21 cases received the treatment for over 24 weeks. Conclusions Adverse events are common during the patients with recurrent hepatitis C after liver transplantation who received low dose Peg-IFN plus RBV treatment. Most of these adverse events are controllable. It is safe for patients with recurrent hepatitis C after liver transplantation to receive low dose Peg-IFN plus RBV treatment.